Other Events ·
Coya Therapeutics delays FTD trial to 2027 as it initiates ALS open-label extension
COYACoya Therapeutics, Inc.
Coya Therapeutics announced the initiation of an open-label extension for its Phase 2/3 ALSTARS Trial evaluating COYA 302 in amyotrophic lateral sclerosis (ALS), expected to begin in November 2026. To prioritize resources toward this ALS development, the company delayed the planned start of a Phase 2 clinical trial for frontotemporal dementia (FTD) from late 2026 to 2027. The firm maintains its cash runway guidance, expecting existing funds to support operations into the second half of 2027, beyond the anticipated ALSTARS topline data readout. Coya Therapeutics is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases.